These genetic alterations closely resemble the genomic profile of other sarcomas that respond to CDK4/6 inhibition, suggesting a potential therapeutic strategy involving CDK4/6 inhibitors, either as a single agent or in combination with MDM2 inhibitors, for BCOR-fusion-positive sarcomas [54]. Here, CDK4 is linked to sarcoma.